Catalyst Pharmaceuticals is committed to improving the lives of people with rare diseases

June is Myasthenia Gravis Awareness Month

At Catalyst Pharmaceuticals, we understand that receiving a rare disease diagnosis can be extremely difficult. Often patients feel isolated and hopeless. That’s why we believe that, when you’re battling a rare disease—it’s all about the company you keep.

Our company is committed to developing novel, safe, and efficacious therapies that will improve the lives of people with rare and ultra-rare diseases.

Significant advances have been made in fighting rare diseases over the past decades. In the 10 years prior to the passage of the Orphan Drug Act in 1983, fewer than 10 drugs for rare diseases were approved by the U.S. FDA. Since then, an estimated 400 rare-disease...